Immunotherapy Drug Durvalumab Shines in Most Recent Mesothelioma Trial
Another new study confirms what Johns Hopkins researchers have been banking on – that the immunotherapy drug durvalumab can make chemotherapy more effective for mesothelioma patients. Durvalumab (IMFINZI) is an immune checkpoint inhibitor. It works by blocking the action of PD-1, a protein that mesothelioma cells use to protect themselves. Researchers theorized that deactivating PD-1 with the immunotherapy drug durvalumab might make mesothelioma tumors more responsive to chemotherapy. The latest study results, published in Nature Medicine, suggest that they were right. The findings could have implications for people around the world with inoperable malignant mesothelioma. How the Immunotherapy Drug Durvalumab Helps Fight Mesothelioma Durvalumab is one of several immune checkpoint inhibitors showing promise for mesothelioma in recent years. Keytruda (pembrolizumab)…